Federal Circuit Affirms District Court Decision Holding Asserted Software Claims Invalid as Directed to Patent Ineligible Subject Matter

Oct 28, 2016

Reading Time : 1 min

The Federal Circuit affirmed the district court’s decision and found that the claims were directed to a patent-ineligible abstract idea: the concept of analyzing records of human activity to detect suspicious behavior.  The court agreed that the claimed method is nothing more than a combination of several abstract ideas previously found ineligible under § 101, including collecting information, analyzing information and presenting the results of an abstract process.

The court contrasted the claims of the ’500 patent with those at issue in McRO, Inc. v. Bandai Namco Games America, Inc. In McRO, the court found McRO’s claims patent-eligible because they were directed to a specific asserted improvement in computer animation that used rules to accurately synchronize animated lips for on screen characters. This was previously done by animators; thus, the rules were critical to the implementation of the process on a computer. In contrast, the claims in the ’500 patent did not use rules to improve an existing technological process, but rather merely implemented an old practice in a new environment

Turning to step two of the patent-eligibility inquiry, the court found that the claims fail to add something more or transform the claimed abstract idea of collecting information and analyzing into a patent-eligible application of the abstract idea. The ’500 patent claims merely use generic computer elements such as microprocessors and user interfaces, which are not enough to transform an otherwise abstract idea into patent-eligible subject matter. Moreover, the claims do not propose a solution or overcome a problem specifically arising in the realm of computer technology.

The court also rejected FairWarning’s argument that the ’500 patent does not pre-empt the field of Health Insurance Portability and Accountability Act (HIPAA) regulation compliance. The court held that the absence of complete field pre-emption does not demonstrate patent eligibility, and the fact that the ’500 patent’s claims might not pre-empt the entire field of HIPAA compliance does not make them any less abstract.

FairWarning IP, LLC v. Iatrict Systems, Inc., Case No. 2015-1985 (Fed. Cir. Oct. 11, 2016).

Share This Insight

Previous Entries

IP Newsflash

December 18, 2025

The Federal Circuit recently vacated a $20 million jury verdict in favor of a patentee and remanded with instructions to dismiss the case for lack of subject matter jurisdiction, finding that the patentee did not own the asserted patents at the time it filed suit and therefore lacked standing.

...

Read More

IP Newsflash

December 17, 2025

The Federal Circuit recently affirmed a Patent Trial and Appeal Board decision finding claims that had been subject to an ex parte reexamination unpatentable. As a threshold issue, the court held that IPR estoppel under 35 USC § 315(e)(1) does not apply to ongoing ex parte reexaminations. Accordingly, the Patent Office did not err in continuing the reexamination after issuing final written decisions in co-pending IPRs.

...

Read More

IP Newsflash

December 15, 2025

The District of Delaware recently denied a defendant’s motion to dismiss plaintiff’s demand for enhanced damages based on willful infringement pursuant to 35 U.S.C. § 284, explaining that neither a demand for damages under § 284 nor an accusation of willful infringement amount to a claim for relief that can be subject to dismissal under Rule 12(b)(6).

...

Read More

IP Newsflash

December 9, 2025

The Federal Circuit recently denied a petition for a writ of mandamus that challenged the PTO Director’s reliance on “settled expectations” to discretionarily deny two inter partes review (IPR) petitions. In so doing, the court explained that, while it was not deciding whether the Director’s use of “settled expectations” was correct, the petitioner’s arguments about what factors the Director may consider when deciding whether to institute an IPR or post-grant review (PGR) are not generally reviewable and did not provide sufficient basis for mandamus review here.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.